癌症患者中的 COVID-19 问题。
COVID-19 in cancer patients.
机构信息
Institute of Immunity and Transplantation, Royal Free Hospital and University College London, UK.
Nawaloka Hospital Research and Education Foundation, Nawaloka Hospitals, Colombo, Sri Lanka.
出版信息
Trans R Soc Trop Med Hyg. 2022 Sep 10;116(9):767-797. doi: 10.1093/trstmh/trac015.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has currently affected >220 million individuals worldwide. The complex interplay of immune dysfunction, active malignancy, the effect of cancer treatment on the immune system and additional comorbidities associated with cancer and COVID-19 all affect the outcomes of COVID-19 in patients with cancer. We have discussed the published findings (through the end of September 2021) on the effects of cancer on the morbidity and mortality of COVID-19, common factors between cancer and COVID-19, the interaction of cancer and COVID-19 treatments, the impact of COVID-19 on cancer clinical services, immune test findings in cancer patients with COVID-19 and the long-term effects of COVID-19 on cancer survivors.
2019 年冠状病毒病（COVID-19）由严重急性呼吸系统综合征冠状病毒 2 引起，目前已在全球影响超过 2.2 亿人。免疫功能障碍、活动性恶性肿瘤、癌症治疗对免疫系统的影响以及与癌症和 COVID-19 相关的其他合并症的复杂相互作用，均会影响癌症患者 COVID-19 的结局。我们已讨论了癌症对 COVID-19 发病率和死亡率影响的已发表研究结果（截至 2021 年 9 月底）、癌症和 COVID-19 之间的共同因素、癌症和 COVID-19 治疗的相互作用、COVID-19 对癌症临床服务的影响、COVID-19 癌症患者的免疫检测结果以及 COVID-19 对癌症幸存者的长期影响。
Zotero 插件